<SEC-DOCUMENT>0001004878-18-000046.txt : 20180223
<SEC-HEADER>0001004878-18-000046.hdr.sgml : 20180223
<ACCEPTANCE-DATETIME>20180223161654
ACCESSION NUMBER:		0001004878-18-000046
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20180223
DATE AS OF CHANGE:		20180223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-205444
		FILM NUMBER:		18636729

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosuppddeewar2-18.txt
<TEXT>

PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement dated                      Registration No. 333-205444
 December 8, 2016)


                               CEL-SCI CORPORATION
                               Series DD Warrants
                               Series EE Warrants



On February 22, 2018 the Company  extended the expiration  date of its Series DD
and Series EE warrants  until the close of business on July 1, 2018.  The Series
DD and Series EE  warrants  were  issued as part of a  financing  on December 8,
2016.  As a  result  of the  reverse  stock  split  approved  by  the  Company's
shareholders and adopted by the Company's directors:

     o    the  holders  of the  Series DD  warrants  are  entitled  to  purchase
          1,360,960 shares of the Company's common stock at an exercise price of
          $4.50 per share; and

     o    the holders the Series EE warrants are entitled to purchase  1,360,960
          shares of the Company's common stock at an exercise price of $4.50 per
          share.



..

























                  Prospectus Supplement dated February 23, 2018
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
